CTV National News: Speaking traditional language improves health in Indigenous community, study says
CTV National News: Speaking traditional language improves health in Indigenous community, study says
Community members are passing on traditional Indigenous language and names to continue cultural connection. CTV News' Allison Bamford reports.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
21 minutes ago
- CTV News
Political, health leaders among more than 80 new appointees to the Order of Canada
The Order of Canada medals are displayed during an investiture ceremony at Rideau Hall in Ottawa on Wednesday, September 23, 2015. THE CANADIAN PRESS/Sean Kilpatrick OTTAWA — The prime minister's incoming chief of staff and two doctors who led Canadians through the COVID-19 pandemic are among 83 appointments to the Order of Canada, being announced today by Gov. Gen. Mary Simon. The list includes Marc-André Blanchard, who takes over in July as Prime Minister Mark Carney's chief of staff. Blanchard previously worked as a lawyer and as Canada's ambassador and permanent representative to the United Nations. Dr. Theresa Tam, who retired in June as Canada's chief public health officer, will be inducted as an officer of the Order of Canada. Tam became a household name as she led the country's public health response to the COVID-19 pandemic. Dr. Bonnie Henry, who led British Columbia's pandemic response as the provincial health officer and is heading its public health response to the drug overdose crisis, joins Tam among the new appointees at the officer level. More than 8,200 people have been appointed to the Order of Canada since its creation in 1967. Many are national household names including politicians, musicians, actors and writers. Many others are awarded for their contributions at a more local level to multiple fields, including science, medicine, education and the arts. The latest list includes several politicians, including former finance minister John Manley, who is being promoted to the companion level after initially being inducted as an officer of the Order of Canada in 2009. Companion is the highest level within the order, followed by the officer level, which are both generally awarded for contributions to Canada as a whole, or 'humanity at large.' A member of the Order of Canada recognizes distinguished service to a specific community or within a specific field. Maureen McTeer, a lawyer and author who has worked on gender issues and health guidelines, will be appointed as an officer. McTeer, who is married to former prime minister Joe Clark, is currently a visiting professor in the faculty of common law at the University of Ottawa. Canadian writer Miriam Toews and opinion researcher Bruce Anderson were also named to the Order of Canada. 'We proudly recognize each of these individuals whose dedication and passion for service not only enrich our communities but also help shape the fabric of our nation,' Simon said in a statement released with the list. 'Together, they inspire us to strive for greatness and to foster a future filled with hope and possibility.' Others appointed to the Order of Canada include biologist Ford Doolittle, musician Gilbert Donald Walsh, former senator Claudette Tardif and poet Louise Bernice Halfe, whose Cree name is Sky Dancer. Genealogist Stephen White received an honorary appointment. The governor general is expected to take part in Canada Day celebrations at Lebreton Flats Park on Tuesday, where she will preside over an Order of Canada ceremony, investing five people whose appointments were announced before today. The inductees being announced today will be invested in ceremonies to be scheduled at a later date. Catherine Morrison, The Canadian Press
CTV News
an hour ago
- CTV News
Peeters mushrooms recalled in Ontario and Quebec for listeria
Peeters Mushroom Farm sliced mushrooms distributed in Ontario and Quebec are being recalled for possible Listeria monocytogenes contamination. The recall was announced Sunday and was triggered by Canadian Food Inspection Agency (CFIA) test results. The CFIA will be conducting a food safety investigation, which may lead to the recall of other products, according to the notice. The affected products are: Brand: none; product: Thin Sliced Mushroom, 2.27 kg; UPC: none; code: 175, 190 Brand: none; product: Thick Sliced Mushroom, 2.27 kg; UPC: none; code: 175, 190 Brand: Peeters Mushroom Farm; product: Sliced Mushrooms, 227 g; UPC: 0 33383 67600 5; code: BEST BEFORE 25JL04 Brand: Peeters Mushroom Farm; product: Cremini Sliced; 227 g; UPC: 0 68414 96960 3; code: BEST BEFORE 25JL04 According to the recall, food contaminated with Listeria monocytogenes may not appear or smell spoiled but may still make you sick. Symptoms can include vomiting, nausea, persistent fever, muscle aches, severe headache and neck stiffness. Pregnant women, elders and people with weakened immune systems are at increased risk. The recall notes that while pregnant women may experience mild symptoms, an infection could lead to premature delivery, infection of the newborn or even stillbirth. Severe cases of illness can lead to death. The CFIA is asking consumers to not consume, serve, use, sell, or distribute the affected products and to either dispose the recalled products or return them to the location of purchase. Consumers are also being asked to contact a health-care provider if they become sick due to the recalled products.
National Post
2 hours ago
- National Post
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
Article content Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Article content Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Article content Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET Article content ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects. Article content Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade ≥3 adverse events, there were no treatment‑related serious adverse events (SAEs) and there were no discontinuations due to treatment-related adverse events. Adverse events that occurred in more than one subject included injection site reactions (24% aritinercept, 13% placebo), headache (11% aritinercept, 7% placebo), upper respiratory tract infection (7% aritinercept, 0% placebo) and back pain (4% aritinercept, 0% placebo). All injection site reactions were Grade 1. Article content Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins (antibodies). Specifically, mean reductions from baseline to Day 28 of up to 48%, 55% and 20% were observed for immunoglobulin A (IgA), immunoglobulin M (IgM) and immunoglobulin G (IgG), respectively. Article content 'Dual inhibition of BAFF and APRIL to modulate B cells, including plasma cells, holds great promise in the treatment of a wide range of autoimmune immune diseases where these cells produce disease-causing autoantibodies,' said Dr. Greg Keenan, Chief Medical Officer of Aurinia. 'Based on today's positive results, which indicate robust and long‑lasting pharmacodynamic effects supportive of once-monthly dosing, we plan to initiate clinical studies of aritinercept in at least two autoimmune diseases in the second half of this year.' Article content Webcast & Conference Call Details Article content A webcast and conference call will be hosted today, June 30, at 8:30 a.m. ET. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. Article content About Aurinia Article content Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA‑approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept (AUR200), a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Article content Forward-Looking Statements Article content This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with the development of aritinercept and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia's most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval (SEDAR) website at or the U.S. Securities and Exchange Commission's Electronic Document Gathering and Retrieval System (EDGAR) website at and on Aurinia's website at Article content Article content Article content
